Remove Economics Remove Medical Remove Public Trading
article thumbnail

How Private Equity uses ‘Roll-up’ Strategies to Drive Investment Returns

OfficeHours

In this industry, owning 50 to 100 or more veterinary centers gives you procurement advantages in that you can buy much higher volumes of suppliers (syringes, medical equipment, etc.) For example, relevant platforms in this space include AmeriVet (owned by AEA and ADIA) and VetCor (owned by Oak Hill).

article thumbnail

Private Equity’s Increasing Consolidation of Oncology Practices 

Focus Investment Banking

according to a recent report by researchers from the Harvard Medical School and the Harvard Business School that was published in JAMA Internal Medicine. A big part of oncology is buying and billing chemotherapy, and we're able to improve their economics there substantially with national buying power,” Patton told OBR.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2022 Life Sciences M&A Year in Review

Cooley M&A

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40
article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Of the 20 largest public deals in the healthcare sector in 2021, 14 featured all?cash

M&A 40
article thumbnail

Momentum Builds for Ophthalmology Recapitalizations

Focus Investment Banking

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. However, the type of larger company that would be interested in buying physician practice management (PPM) companies has been unknown.

article thumbnail

Cooley’s 2024 Life Sciences M&A Year in Review: M&A Slims Down in 2024, but Will Appetites Grow in 2025?

Cooley M&A

Looking ahead, expect the fruits of these efforts to free up valuable resources capital and management bandwidth that can be redirected toward higher-value, strategic acquisitions in 2025 as the general economic backdrop (inflation, interest rates, antitrust) looks to become more conducive to bigger bets.

M&A 64